Aspirin for Cardiovascular Prevention in Type 2 Diabetes

Introduction and Drug Overview

Should aspirin be used in the primary prevention of cardiovascular mortality and morbidity in patients with type 2 diabetes? Aspirin has long been thought to prevent and reduce the likelihood of cardiovascular disease. However, a growing body of research has shown otherwise. This paper, with the help of selected literature, argues that aspirin cannot reliably play a role in the prevention and reduction of cardiovascular disorders in this population.

Aspirin, also known as acetylsalicylic acid, is a salicylate-based medicine commonly used for the relief of minor pain and aches, and as an antipyretic agent to reduce fever. It was isolated and purified by Felix Hoffmann, a German chemist. Salicylic acid is the main metabolic product of aspirin and has been recognized as an important component of the metabolic systems of both animals and humans. In humans, salicylic acid is considered part of the normal diet, and the synthesis of aspirin occurs in an endogenous manner.¹

Aspirin is known to prevent and slow the production of thromboxane — an effect referred to as its antiplatelet action. When blood vessels are damaged, platelets attach to thromboxane, causing a clump of platelets to form on the inner wall of the vessel. These platelet patches can grow into larger masses and may block the vessel entirely. Given this mechanism, aspirin is administered to cardiac patients in low doses to prevent the formation of such platelet aggregations.

Most studies conducted to date have suggested that aspirin can be used for the prevention of heart attacks. In many reported cases, administering aspirin after a first heart attack helps prevent a second one. Clinical studies have also documented aspirin's role in reducing the risk of initial cardiac events.

Previous Literature on Aspirin and Cardiovascular Prevention

The literature identifies two primary modes of aspirin use for cardiovascular prevention: primary prevention and secondary prevention. In primary prevention, aspirin is given to healthier populations to reduce the risk of a first heart attack. Secondary prevention applies to individuals already diagnosed with cardiovascular conditions. Past studies have found that low doses of aspirin can reduce the risk of heart attacks and ischemic strokes by approximately 20%. However, aspirin is not without risks: it has been associated with double the risk of hemorrhagic strokes and bleeding from blood vessels. Furthermore, people without pre-existing cardiovascular conditions benefit considerably less than those with established heart disease. Studies have reported more than a 10% reduction in heart attack risk among cardiac patients already diagnosed.²

In discussions about primary prevention, aspirin has sometimes been proposed as a component of "polypills." The use of polypills, however, has generally been rejected. The U.S. Preventive Services Task Force has recommended that the use of such medications be based on the personal preferences, informed consent, and individual health conditions of each patient.

One major clinical trial found that aspirin does not appear to have a meaningful effect on low-risk cardiac patients. Risk reduction was observed primarily in patients with serious heart conditions: a 12% risk reduction was found in patients with serious myocardial infarction, while for patients with low-risk myocardial infarction the reduction was only 0.18%. No significant effect was seen in stroke reduction. Side effects observed included extra-cranial bleeding and gastrointestinal hemorrhages. Importantly, the risk factors associated with serious heart disease were found to overlap with those for gastrointestinal and extra-cranial bleeding. The study therefore concluded that the overall effect of aspirin in reducing cardiovascular risk is of uncertain value, and that the bleeding risks posed by aspirin may be greater than the risks of the cardiac events it aims to prevent. The authors called for further trials to better quantify these risks in both primary and secondary prevention settings.¹

Another important finding revealed that the effects of aspirin in primary prevention were smaller than anticipated, particularly for women. A ten-year study found that 100 mg of aspirin administered to women produced no measurable reduction in heart attack risk. This raised the question of gender differences in aspirin response. Earlier studies — including one from 1985 — had concluded that aspirin protects anyone aged 40 to 84 from heart attack, finding that men who took 325 mg of aspirin regularly were at a 44% lower risk of cardiac events. By contrast, the more recent study found only a 9% reduction in heart attack risk among women taking aspirin compared to those on placebo — a substantially smaller benefit.³

A study published in the Drugs and Therapeutics Bulletin also concluded that aspirin is not helpful in preventing cardiovascular risk in individuals without established heart disease. The bulletin noted that since the mid-2000s, many clinicians had recommended daily aspirin to patients with risk factors including type 2 diabetes and high blood pressure. Drawing on six prior studies, the bulletin found that while daily aspirin does lower the risk of heart attack, it doubles the risk of gastrointestinal hemorrhage — a potentially fatal complication. People without cardiac disease who take aspirin daily do not benefit from meaningful heart-attack risk reduction, yet they face increased risk of internal bleeding.³ These findings were supported by the Royal College of General Practitioners, which called on doctors and practitioners to improve patient awareness of the risks associated with daily aspirin use.⁴

Taken together, these studies suggest that daily aspirin may offer some benefit to those who have already experienced serious cardiac events, but provides minimal benefit — and poses notable harm — in primary prevention, particularly for lower-risk individuals. A more recent study by the British Medical Journal specifically investigated diabetic patients without heart disease and found that this group derives no benefit from aspirin in preventing a first heart attack. Only diabetics who have previously experienced a heart attack appear to benefit from aspirin in terms of preventing future events.³

The first study — "Use of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease in Diabetic Patients in an Ambulatory Care Setting in Spain" — was conducted on a diabetic patient population, noting that diabetics face elevated cardiovascular risk compared to the general population. The study examined the use of specific drugs and medications to reduce or prevent heart attacks in diabetics in Spain. It noted that the American Diabetes Association had approved the use of salicylic acid for both primary and secondary prevention in appropriate patient categories. The primary aim was to assess the effect of recommended medications on preventive care for diabetics in Spain. Data spanned two years of patient records and included variables such as age, sex, social status, and primary care center identification. Key measures included aspirin or other drug use, clinical parameters, rates and incidence of comorbidities, and the proportion of patients meeting therapeutic targets. Chi-square tests, descriptive statistics, and regression analysis were used to calculate statistical significance.⁵

The study's data indicated that aspirin use among diabetics in Spain is relatively low. The findings point toward a limited or absent effect of aspirin on diabetics who have not previously experienced a heart attack. The data also suggests increased risks from aspirin use in diabetic patients, particularly relating to internal bleeding. A limitation of the study is that it did not explicitly recommend reducing aspirin use in this population, despite the evidence pointing in that direction.

Study 1: Aspirin Use in Diabetic Patients in Spain

The patient data collected also lacked sufficient variance relative to the study's objectives. Ideally, the analysis would have focused on the side effects of aspirin specifically observed in diabetics within primary and secondary prevention categories. Nonetheless, a notable strength of the study is its sample size: although data collection spanned only two years, more than 4,000 patients were included. One finding worth highlighting is that aspirin use was higher among older patients than younger patients — a pattern that warrants attention, as the additional risks posed by aspirin suggest that older patients may in fact need closer monitoring or reduced dosing. The study did not adequately explain why aspirin was used less frequently in younger patients, which would have strengthened its conclusions.

The second study — "Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes" — investigated the effects of low-dose aspirin in patients with type 2 diabetes. Conducted over six years in Japan across more than 163 medical institutions, the study enrolled more than 2,600 patients who had been followed for five years after a type 2 diabetes diagnosis. The trial design was open-ended, randomized, and outcome-based. While standard high-dose aspirin therapy uses 325 mg per day for high-risk patients, this study administered 80–100 mg of aspirin daily to patients at lower cardiovascular risk. Patients were divided into two cohorts: one group received aspirin and one did not. The study found no significant difference in heart attack risk reduction between the two groups following aspirin administration. A secondary finding concerned the side-effect profile: because the dosage was lower, fewer adverse effects were observed, but the overall conclusion remained that low-dose aspirin did not reduce atherosclerotic events in this population.⁶

This study is notable for its greater diversity and larger scope compared to the first study. While formal statistical techniques beyond confidence intervals were not extensively used, the breadth of the data and the robustness of the randomized design make the findings more conclusive. The study confirmed that low-dose aspirin has minimal effect on primary prevention in patients with type 2 diabetes.

A significant limitation, however, is that the study focused exclusively on primary prevention patients. Including a secondary prevention cohort — patients already diagnosed with cardiac conditions — would have strengthened the study considerably, as these patients represent a population in which aspirin effects are expected to be more pronounced. The findings reinforce the need for further research examining the effects of both low and high doses of aspirin across primary and secondary prevention contexts in diabetic patients.

The studies analyzed in this paper indicate that aspirin has limited effects on diabetic patients in the primary care setting. Recent secondary and tertiary literature suggests that current regimens for administering aspirin — in both low and high doses — need to be revisited. Although there may be some reduction in cardiovascular risk following aspirin use, the risks posed by aspirin are potentially more serious than those associated with the cardiac events it is intended to prevent. Cardiovascular disease prevention strategies for diabetic populations must carefully weigh these competing risks.

Conclusion

5. Sicras-Mainar A, Navarro-Artieda R, Rejas-Gutierrez J, Fernandez-de-Bobadilla J, Frias-Garrido X, and Ruiz-Riera R. Use of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease in Diabetic Patients in an Ambulatory Care Setting in Spain. BMC Family Practice. 2007; 8:60.

6. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, and Saito Y. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial. JAMA. 2008; 300(18):2134–2141.